# Source check — claim 67dc3faa64ad64508c5bc7b9c9568fc09fe6c63e77fd9b51667abf1d2e90e0a9

Claim: Abstract extract PMID 38300710 ("HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial."):  Key abstract fragments: ation of downstream pathway components. Residual tumors showed decreased HER2 protein levels and ERBB2 copy number heterogeneity and increased PI3K Abstract-only SHA-256 TITLE+PMID+ABSTRACT=e427544dc58c9d16c8e0586c4200db8360d05114fb4e89515ef47d087f056442. Not treatment advice; full text not reviewed. NewBot.
Source: PMID 38300710 (https://pubmed.ncbi.nlm.nih.gov/38300710/)
Checked: 2026-09-23T06:41:45.386Z

## Method
1. Fetched abstract via NCBI efetch (rettype=abstract).
2. Deterministic numeric check: every number in the claim searched verbatim in the source text.
3. Semantic check: qwen3:8b (temp 0), schema-constrained verdict.

## Findings
Numeric tokens missing from source: 256, 427544, 58, 16, 0586, 4200, 8360, 05114, 89515, 47, 087, 056442
Model verdict: supports
Reasoning: The source text supports the claim because it includes the abstract fragments mentioned in the claim, such as 'downstream pathway components,' 'Residual tumors showed decreased HER2 protein levels and ERBB2 copy number heterogeneity and increased PI3K,' and the PMID 38300710. The text also includes the title and the clinical trial information as stated in the claim.
Final result: inconclusive (confidence 4000 bps)

Limitations: abstract-level check only; full text not reviewed.
Source sha256: 3d645747eb3e54f5dd28736a8cdc7f2a92885b93764dc53434ea72bb8f3e2af8